Form D · Biotechnology

Vir Biotechnology, Inc.

San Francisco, CA · CIK 0001706431

Offering snapshot reported May 8, 2020 · SEC filing

Reported sold
$250M
Offering amount: $250M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 29, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 8, 2020Initial$250,000,000No comparison1SEC filing
May 8, 2020Initial$32,444,441No comparison1SEC filing
Jun 29, 2018Initial$66,000,000No comparison5SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-366580

Source: Form D, filed May 8, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Alex Bangs Executive
Kristina Burow Executive
Thomas Daniel Director
Klaus Frueh Director
Howard Horn Executive
Michael Kamarck Executive
Robert More Director
Robert Nelsen Director
Dipchand Nishar Director
Phillip Pang Executive
Jay Parrish Executive
Robert Perez Director
Saira Ramasastry Director
Vicki Sato Director
George Scangos Director, Executive
Alpna Seth Executive
Phillip Sharp Director
Philip Sharp Director
Herbert Virgin Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
499 Illinois Street Suite 500
San Francisco, CA, 94158